DAVID MASSEY: Open Payments
NPI 1689959421 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$517 in 23 payments from 12 companies in 2025. Trend: 2023 $183 · 2024 $91 · 2025 $517
Food & beverage: $517
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 3 | $89 |
| Neurocrine BioSciences, Inc. | 3 | $74 |
| Lundbeck LLC | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Alkermes, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| E.R. Squibb & Sons, L.L.C. | 1 | $32 |
| Biogen, Inc. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
Products named: REXULTI, FANAPT, INGREZZA, AUSTEDO XR, ARISTADA, CAPLYTA, COBENFY, ZURZUVAE.
Industry payments across OK — which companies pay providers there.
